Physician profile
Danail Vatev
NPI 1144395849
$5,466.82
in general payments reported to CMS, 2019-2025
25 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $758 · 2021: $1,250 · 2022: $961 · 2023: $536 · 2024: $732 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $987.56 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $933.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $787.99 | 2019-2025 | Airsupra |
| Abbvie INC. | $551.77 | 2020-2023 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $399.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $352.88 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $233.65 | 2019-2022 | |
| Exact Sciences Corporation | $198.58 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $150.99 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Lundbeck LLC | $106.34 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $104.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $83.36 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.32 | 2019-2022 | |
| Redhill Biopharma INC. | $74.53 | 2020-2021 | |
| Amgen INC. | $73.48 | 2024 | Repatha, Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $72.34 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $56.20 | 2019-2021 | |
| Preventric Diagnostics, INC. | $42.28 | 2021 | |
| Abbott Laboratories | $35.87 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $35.82 | 2019 | |
| Allergan, INC. | $30.39 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $28.58 | 2022-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.53 | 2021 | |
| Horizon Therapeutics Plc | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danail Vatev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.